Leslie Livingston
BA (Hons)
Assistant Research Fellow
New Zealand Brain Research Institute, Christchurch
Email: leslie.livingston@nzbri.org
Phone: (+64 3) 928 1330
Publications
Provided on request for non-commercial personal use by researchers.
2024
(2024). Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 16(2), e12601.. 10.1002/dad2.12601
(2024). Higher Frequency of Stuttered Disfluencies Negatively Affects Communicative Participation in Parkinson's Disease. Journal of Speech Language and Hearing Research, 1-12. 10.1044/2024_JSLHR-24-00018
(2024). Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease. Neurology, 102(12), e209301. 10.1212/WNL.0000000000209301
2023
(2023). The New Zealand Parkinson’s Progression Programme. Journal of the Royal Society of New Zealand, 53, 466-488. 10.1080/03036758.2022.2111448
2021
(2021). Higher perceived stress and exacerbated motor symptoms in Parkinson's disease during the COVID-19 lockdown in New Zealand. The New Zealand Medical Journal, 134, 44-51.
(2021). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. Movement Disorders Clinical Practice, 8, 390-399. 10.1002/mdc3.13151
2020
(2020). Microstructural integrity of the major nuclei of the thalamus in Parkinson’s disease. bioRxiv, 2020.05.21.1096. 10.1101/2020.05.21.109660
(2020). Cognitive tests that identify high risk of conversion to dementia in Parkinson's disease. bioRxiv, 2020.05.31.1268. 10.1101/2020.05.31.126870
2019
(2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Frontiers in Neurology, 10, 391. 10.3389/fneur.2019.00391
2017
(2017). Caregiver burden is increased in Parkinson’s disease with mild cognitive impairment (PD-MCI). Translational Neurodegeneration, 6(17). 10.1186/s40035-017-0085-5
2016
(2016). Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting. Parkinsonism & Related Disorders, 22, 54-61. 10.1016/j.parkreldis.2015.11.008
(2016). Different PD-MCI criteria and risk of dementia in Parkinson’s disease: Four year longitudinal study. npj Parkinson's Disease, 2, 15027. 10.1038/npjparkd.2015.27
2015
(2015). Tracking Parkinson's disease over one year with multimodal magnetic resonance imaging in a group of older patients with moderate disease. PLOS ONE, 10, e0143923. 10.1371/journal.pone.0143923
2014
(2014). Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease dementia: an ASL-MRI study. Journal of Cerebral Blood Flow & Metabolism, 34, 964-970. 10.1038/jcbfm.2014.40
(2014). Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study. Translational Neurodegeneration, 3.
2013
(2013). White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology, 80, 1841-1849. 10.1212/WNL.0b013e3182929f62
2012
(2012). The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson’s disease. Neuropsychologia, 50, 3338-3347. 10.1016/j.neuropsychologia.2012.09.025
(2012). Grey matter atrophy in cognitively impaired Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry, 83(2), 188-194. 10.1186/2047-9158-1-17
(2012). Reduced striatal volumes in Parkinson’s disease: a magnetic resonance imaging study. Translational Neurodegeneration, 1(1), 17. 10.1186/2047-9158-1-17
2011
(2011). Characterizing mild cognitive impairment in Parkinson’s disease. Movement Disorders, 26(4), 629-636. 10.1002/mds.23592
(2011). Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain, 134(3), 845-855. 10.1093/brain/awq377
2010
(2010). The MoCA: Well-suited screen for cognitive impairment in Parkinson’s disease. Neurology, 75, 1717-1725. 10.1212/WNL.0b013e3181fc29c9
Abstracts and Short papers
2020
(2020). Neuropsychiatric symptoms are associated with dementia in Parkinson’s disease but not predictive of it. MedRxiv, 2020, 09, 01, 20186312. https://doi.org/10.1101/2020.09.01.20186312
2016
(2016). Risk of dementia in Parkinson’s disease: Towards optimal short cognitive testing. Proceedings of the 34th International Winter Conference on Brain Research, 1.
(2016). Amyloid imaging and cognition in Parkinson’s disease: Interim report. Proceedings of the 34th International Winter Conference on Brain Research, 3.
2015
(2015). Longitudinal magnetic resonance spectroscopy in Parkinson’s disease. Proceedings of the 21st Annual Meeting of the Organization for Human Brain Mapping.
(2015). White matter lesions contribute to future dementia in Parkinson’s disease. Proceedings of the 21st Annual Meeting of the Organization for Human Brain Mapping.
2014
(2014). Cognitive status in Parkinsons disease characterised by magnetic resonance spectroscopy. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, 34.
(2014). Individualised medicine: Predicting dementia in Parkinsons disease. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, Abstract 8.1.
(2014). Comparing mild cognitive impairment criteria in Parkinsons disease: influence on dementia onset. Proceedings of the International Australasian Winter Conference on Brain Research (AWCBR), Queenstown, New Zealand, 32, Abstract 6.4.
2013
(2013). Current perspectives on Parkinsons disease: Cognition to the fore. Proceedings of the 31st Australasian Winter Conference on Brain Research 2013, Queenstown, Volume 31, Abstract 29.
(2013). Domain specific cognitive dysfunction in Parkinson’s Disease and associated pattern of grey matter atrophy. Proceedings of the Movement Disorders Society 17th International Congress - Sydney, Abstract 572..
(2013). Reduced default mode network connectivity and autobiographical memory in mild cognitive impairment. Proceedings of the 31st Australasian Winter Conference on Brain Research 2013, Queenstown, Volume 31, Abstract 27.
(2013). Serial DTI and cognitive decline in Parkinsons disease. Proceedings of the Movement Disorders Society 17th International Congress, Sydney, Movement Disorders, 28 Supplement 1, 555.
(2013). Progression in cognitive function of Huntington patients relative to controls: a 12 months study. Proceedings of the Movement Disorders Society 17th International Congress, Sydney, Movement Disorders, 28 Supplement 1, Abstract 760 .
(2013). Proceedings of the Movement Disorders Society 17th International Congress, Sydney, Movement Disorders, 28 Supplement 1, Abstract 758.
(2013). Criteria for Parkinson’s disease with mild cognitive impairment associated with increased progression to dementia. Proceedings of the 31st Australasian Winter Conference on Brain Research 2013, Queenstown, Volume 31, 58.
2012
(2012). Impairment of implicit prediction in rhythmic saccadic movement in symptomatic huntington patients (Abstract). Journal of Neurology, Neurosurgery, and Psychiatry, 83:Suppl 1, A34. 10.1136/jnnp-2012-303524.104
(2012). The effectiveness of cognitive and reflexive saccade measures in discriminating Huntingtons disease from healthy controls (Abstract). European Journal of Neurology, 19 Suppl 1, Poster 1661. 10.1111/j.1468-1331.2012.03888.x